Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01656447 · ClinicalTrials.gov registry record
Scleroderma Registry & Repository at the Hospital for Special Surgery
A clinical trial of Scleroderma, sponsored by Hospital for Special Surgery, New York.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT01656447 is a study of Scleroderma that is actively recruiting participants, run by Hospital for Special Surgery, New York. The registered enrollment target is 300 participants, below the 389-participant average among 23 other Scleroderma trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01656447, a study of Scleroderma, is actively recruiting participants, sponsored by Hospital for Special Surgery, New York.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objective of the Scleroderma Registry is to support and promote the basic science and clinical research of this complex rheumatic disease at the Hospital for Special Surgery (HSS). The registry facilitates our understanding of the clinical features, pathobiology, genetics of Scleroderma. This will ultimately lead to a potential treatment for this currently untreatable condition.
Conditions Studied
Study Locations (1)
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2006-08 |
| Est. Completion | 2030-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01656447
The ClinicalTrials.gov registry entry for NCT01656447 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 389-participant average among 23 other Scleroderma trials with a reported enrollment target (23% lower). The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Scleroderma appearing as the primary indexed condition, and to 0 interventions.
NCT01656447 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01656447 about?
NCT01656447 is a clinical study titled "Scleroderma Registry & Repository at the Hospital for Special Surgery". The overall objective of the Scleroderma Registry is to support and promote the basic science and clinical research of this complex rheumatic disease at the Hospital for Special Surgery (HSS). The registry facilitates our understanding of the clinical features, pathobiology, genetics of Scleroderma....
What is the current status of trial NCT01656447?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2006-08. Estimated completion is 2030-01.
What conditions does trial NCT01656447 study?
This clinical trial studies the following conditions: Scleroderma.
Who is sponsoring clinical trial NCT01656447?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01656447 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
Platform Clinical Study for Conquering Scleroderma
RECRUITING · Phase 2
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
-
Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.